Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (214)	1/16/2003 3:46:11 PM
From: Jibacoa	Respond to of 3722

XOMA Is up 12.34% on volume of 1,622,151 after positive comments from Ryan Beck & Co.<g> RB considered DNA comments on Raptiva a positive for XOMA. (DNA in the C.C. yesterday projected FDA approval for Raptiva as early as the 4thQ this year.That was about a Q earlier than RB had projected.) RB pointed out that XOMA is expected to receive 25% of profits from Raptiva sales. They reiterated their "Outperform" rating and a 12-month target of $11. Will see if the stock can close today above its Dec.31 H of 4.50 <g> siliconinvestor.com Bernard